Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01681875
Other study ID # U54DA031659
Secondary ID U54DA031659-01
Status Completed
Phase N/A
First received
Last updated
Start date June 2013
Est. completion date July 2014

Study information

Verified date August 2018
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Project 1, Study 1 will evaluate the relationship between nicotine yield of very low nicotine content cigarettes and cigarettes smoked per day, nicotine exposure, discomfort/dysfunction, other health-related behaviors, nicotine/tobacco dependence, biomarkers of tobacco exposure, intention to quit, compensatory smoking, other tobacco use, cigarette characteristics, cognitive function, cardiovascular function, and perceived risk. We will also consider differences between conditions in compliance with product use.


Recruitment information / eligibility

Status Completed
Enrollment 839
Est. completion date July 2014
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age 18+

- Smoke an average of at least five cigarettes per day for at least 1 year

- Breath CO levels > 8 ppm (if = 8 ppm, then NicAlert Strip > 2)

Exclusion Criteria:

- Intention to quit smoking in the next 30 days

- Currently seeking treatment for smoking cessation

- Currently using nicotine replacement therapies or other pharmacotherapies as cessation aid (intermittent use acceptable)

- A quit attempt in the past 30 days resulting in greater than 3 days of abstinence

- Using other tobacco products more than 9 days in the past 30 days

- Significant unstable medical conditions (Any significant change in a serious medical condition occurring during the past 3 months including, cardiovascular disease, COPD, and cancer, as determined by the licensed medical professional at each site)

- Significant unstable psychiatric conditions (Any significant change in psychiatric symptoms during the past 3 months as determined by the licensed medical professional at each site)

- Schizophrenia and schizoaffective disorder

- Psychiatric medication changes in the past 3 months

- Positive toxicology screen for any of the following drugs: cocaine, opiates, methadone, benzodiazepines, barbiturates, amphetamines, methamphetamines, and PCP

1. Marijuana will be tested for but will not be an exclusionary criterion.

2. Participants with valid prescriptions for opiates, benzodiazepines, barbiturates, amphetamines or methadone will not be excluded.

3. Participants failing the toxicology screen will be allowed to re-screen once.

- Blood alcohol level > 0.01

a. Participants failing the blood alcohol screen will be allowed to re-screen once.

- Binge drinking alcohol (more than 9 days in the past 30 days, 4/5 in a 2 hour period(female/male))

- Pregnant or breastfeeding

- Smoking 'roll your own cigarettes' exclusively

- Currently taking anticonvulsant medication

- CO reading >80 ppm

- Systolic BP greater than or equal to 160

a. Participants failing for blood pressure will be allowed to re-screen once.

- Diastolic BP greater than or equal to 100

a. Participants failing for blood pressure will be allowed to re-screen once.

- Systolic BP below 90

a. Participants failing for blood pressure will be allowed to re-screen once.

- Diastolic BP below 50

a. Participants failing for blood pressure will be allowed to re-screen once.

- Heart rate greater than or equal to 115bpm

a. Participants failing for heart rate will be allowed to re-screen once.

- Heart rate lower than 45bpm

a. Participants failing for heart rate will be allowed to re-screen once.

- Indicating any suicidal ideation in the past month or suicide attempts in the past 10 years

- Inability to independently read and comprehend the consent form and other written study materials and measures

- Having participated in a research study during the past three months in which the participant:

1. Smoked a cigarette that was not his/her usual brand cigarette for more than one day

2. Used any tobacco products beyond normal use for more than one day

3. Used any nicotine replacement products or smoking cessation medications for more than one day

Study Design


Related Conditions & MeSH terms


Intervention

Other:
very low nicotine content cigarettes


Locations

Country Name City State
United States Johns Hopkins University Baltimore Maryland
United States University of Minnesota Medical School Duluth Duluth Minnesota
United States Duke University Durham North Carolina
United States University of Minnesota Masonic Cancer Center Minneapolis Minnesota
United States University of Pennsylvania Philadelphia Pennsylvania
United States University of Pittsburgh Pittsburgh Pennsylvania
United States Brown University Providence Rhode Island
United States University of California San Francisco San Francisco California
United States Moffitt Cancer Center Tampa Florida

Sponsors (11)

Lead Sponsor Collaborator
Wake Forest University Health Sciences Brown University, Duke University, H. Lee Moffitt Cancer Center and Research Institute, Johns Hopkins University, M.D. Anderson Cancer Center, Masonic Cancer Center, University of Minnesota, National Institute on Drug Abuse (NIDA), University of California, San Francisco, University of Minnesota, MN, University of Pennsylvania

Country where clinical trial is conducted

United States, 

References & Publications (4)

Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd. Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes. Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):761-9. doi: 10.1158/1055-9965.EPI-11-0644. Epub 2012 Feb 21. — View Citation

Donny EC, Houtsmuller E, Stitzer ML. Smoking in the absence of nicotine: behavioral, subjective and physiological effects over 11 days. Addiction. 2007 Feb;102(2):324-34. — View Citation

Donny EC, Jones M. Prolonged exposure to denicotinized cigarettes with or without transdermal nicotine. Drug Alcohol Depend. 2009 Sep 1;104(1-2):23-33. doi: 10.1016/j.drugalcdep.2009.01.021. Epub 2009 May 15. — View Citation

Hatsukami DK, Kotlyar M, Hertsgaard LA, Zhang Y, Carmella SG, Jensen JA, Allen SS, Shields PG, Murphy SE, Stepanov I, Hecht SS. Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. Addiction. 2010 Feb;105(2):343-55. doi: 10.1111/j.1360-0443.2009.02780.x. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of cigarettes smoked per day End of 6 week intervention
See also
  Status Clinical Trial Phase
Completed NCT01928719 - Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status N/A
Completed NCT01995123 - Behavioral Activation for Smoking Cessation in PTSD N/A
Not yet recruiting NCT03249428 - E-Cigarette Inner City RCT N/A
Recruiting NCT02564289 - Cardiovascular Effects of Chronic Snus Use N/A
Completed NCT01928758 - Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders N/A
Withdrawn NCT01847300 - cSBI-M for Young Military Personnel N/A
Completed NCT01428310 - Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke Phase 1
Completed NCT01570595 - Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV Phase 1/Phase 2
Recruiting NCT00977249 - Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users Phase 2/Phase 3
Active, not recruiting NCT00968513 - Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry Phase 3
Completed NCT00747643 - Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement N/A
Completed NCT01113424 - Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum N/A
Completed NCT00722124 - S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence Phase 2/Phase 3
Completed NCT01228617 - Single-dose Pharmacokinetics of Oral Nicotine Replacement Products N/A
Completed NCT01238627 - Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg N/A
Completed NCT00296647 - Smoking Cessation Intervention: Effectiveness in Primary Care Phase 4
Completed NCT00394420 - Emergency Department Telephone Quitline N/A
Recruiting NCT05487807 - Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia Phase 1
Completed NCT03553992 - An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers N/A
Withdrawn NCT05440721 - Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification N/A